<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03554031</url>
  </required_header>
  <id_info>
    <org_study_id>GenSci PWS CT</org_study_id>
    <nct_id>NCT03554031</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome</brief_title>
  <official_title>A Single Arm, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneScience Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji medical college huazhong university of science &amp; technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Children's Hospital of Zhejiang University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneScience Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of rhGH (Recombinant human growth hormone) injection for
      improving motor development in patients with PWS.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 14, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of the total motor quotient calculated by Peabody Developmental Motor Scale before and after treatment</measure>
    <time_frame>Baseline, 26 weeks, 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gross motor quotient and fine motor quotient calculated by Peabody Developmental Motor Scale before and after treatment</measure>
    <time_frame>Baseline, 26 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of height standard deviation score (SDS) by chronological age before and after treatment</measure>
    <time_frame>Baseline, 4 weeks, 13 weeks, 26 weeks, 39 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight change before and after treatment</measure>
    <time_frame>Baseline, 4 weeks, 13 weeks, 26 weeks, 39 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of BMI (Body mass index) standard deviation score before and after treatment</measure>
    <time_frame>Baseline, 4 weeks, 13 weeks, 26 weeks, 39 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global quotient, locomotor quotient, personal-social development quotient, language quotient, eye and hand coordination quotient, performance quotient and practical reasoning change calculated by Griffiths Mental Development Scale</measure>
    <time_frame>Baseline, 26 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone maturation ( bone age/ chronological age: BA/CA)</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of IGF-1(Insulin-like growth factor 1) SDS</measure>
    <time_frame>Baseline, 4 weeks, 13 weeks, 26 weeks, 39 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1/IGFBP-3 molar ratio</measure>
    <time_frame>Baseline, 4 weeks, 13 weeks, 26 weeks, 39 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>rhGH injection/Jintropin AQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.No control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Growth Hormone (rhGH) Injection</intervention_name>
    <description>Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.</description>
    <arm_group_label>rhGH injection/Jintropin AQ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Signed informed consent from legal guardian of the subjects;

          -  Subjects are willing and able to cooperate to complete scheduled visits, treatment
             plans and laboratory tests and other procedures;

          -  Diagnosed as PWS by gene test;

          -  Age: 1 month (30 days after birth) - 5 years of age;

          -  Male or female;

          -  Calculated by Peabody Developmental Motor Scale, total motor quotient, gross motor
             quotient or fine motor quotient is less than 90 points;

          -  Thyroid function is within the normal reference range or remained within the normal
             reference range by substitution therapy;

          -  No history of rhGH therapy before.

        Exclusion Criteria:

          -  Subjects with abnormal liver or kidney function;

          -  Subjects with obvious central sleep apnea and/or moderate or severe obstructive sleep
             apnea, acute lung infection;

          -  Subjects with chronic diseases that have long-term effects on bone metabolism and body
             composition;

          -  Subjects with congenital skeletal dysplasia, or spine scoliosis with moderate and
             above degree requiring treatment or lameness;

          -  Subjects with history of congenital heart disease, or an echocardiogram showing that
             the structural abnormalities require surgery or interventional therapy or that the
             left ventricular ejection fraction is &lt;40%, or the abnormal electrocardiogram
             requiring intervention;

          -  Subjects with history of convulsions or epilepsy;

          -  Subjects with other systemic chronic diseases;

          -  Subjects with diagnosed tumors;

          -  Subjects with family history of cancers, a previous history of cancer, or considered
             to be a high risk of cancer combinating other information;

          -  Subjects with mental disease;

          -  Subjects with diabetes, or abnormal fasting glucose and researchers believe that may
             affect the safety of the subject;

          -  Subjects with severe obesity;

          -  Subjects with highly allergic constitution or allergy to proteins or investigational
             product or its excipient;

          -  Subjects who took part in other clinical trials within 3 months ;

          -  Subjects who received drug treatment that may interfere with GH secretion or GH action
             within 3 months;

          -  Other conditions in which the investigator preclude enrollment into the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feihong Luo, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaohua Feng</last_name>
    <phone>0431-85170552</phone>
    <email>fengxiaohua@gensci-china.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji medical college huazhong university of science &amp; technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital,Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Children's Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking union medical college hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking university first hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 30, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>May 30, 2018</last_update_submitted>
  <last_update_submitted_qc>May 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

